$50M Stock Sale Priced at $3.50, a Discount to Aclaris' Last Close
ACRS sits 73% above its 52-week low of $2.095.
Summary
Aclaris priced a $50.0M underwritten offering of 7,785,714 common shares at $3.50 and, in lieu of shares for some buyers, pre-funded warrants for 6,500,000 shares at $3.49999. The $3.50 price is below the $3.63 last close, so buyers are getting a modest discount. TCGX, RA Capital, Invus and a large mutual fund are participating, which is a decent endorsement of the story. The raise comes the same morning the company reported positive Phase 1b ATI-052 results, and it follows the August upsizing of the ATM to $150M — this is a bought deal off the existing shelf, not a new program. The offering is expected to close October 28, 2026.
At the time of this announcement, ACRS was trading at $3.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $557.9M. The 52-week trading range was $2.10 to $6.60. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.